Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
about
Antigen-specific active immunotherapy for ovarian cancerAntigen-specific active immunotherapy for ovarian cancerB7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinomaUpdate on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition.Progress and controversies in developing cancer vaccines.Evolution of animal models in cancer vaccine developmentImmunosuppressive networks in the tumour environment and their therapeutic relevanceBreast cancer vaccines: a clinical reality or fairy tale?The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccineMulti-peptide vaccines vialed as peptide mixtures can be stable reagents for use in peptide-based immune therapies.Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions.Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responsesOverlapping synthetic peptides encoding TPD52 as breast cancer vaccine in mice: prolonged survivalA degenerate HLA-DR epitope pool of HER-2/neu reveals a novel in vivo immunodominant epitope, HER-2/neu88-102.New vaccine developmentVaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trialTamoxifen resistance and Her2/neu expression in an aged, irradiated rat breast carcinoma model.MELOE-1 antigen contains multiple HLA class II T cell epitopes recognized by Th1 CD4+ T cells from melanoma patients.Anti-HER2 vaccines: new prospects for breast cancer therapyBiologic and therapeutic role of HER2 in cancer.Use of tumour-responsive T cells as cancer treatment.Recent advances in the development of breast cancer vaccines.Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breastBlood stem cell transplantation for breast cancer: new approaches using pre- peri- post-transplant immunotherapy.Adoptive T-cell therapy for the treatment of solid tumours.Translating tumor antigens into cancer vaccinesControlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumabSynthetic peptides as cancer vaccines.Adenovirus-mediated intratumoral expression of immunostimulatory proteins in combination with systemic Treg inactivation induces tumor-destructive immune responses in mouse modelsPast, present and future targets for immunotherapy in ovarian cancerProspects for immunotherapy of malignant disease.MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells.A Highly Conserved GEQYQQLR Epitope Has Been Identified in the Nucleoprotein of Ebola Virus by Using an In Silico Approach.Peptide-pulsed dendritic cells have superior ability to induce immune-mediated tissue destruction compared to peptide with adjuvantALK a novel lymphoma-associated tumor antigen for vaccination strategies.Peptide-based vaccines for cancer immunotherapy.Vaccination as a treatment for breast or ovarian cancer.Targeting cytotoxic T lymphocytes for cancer immunotherapy.HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ.
P2860
Q24193567-4C7EBAB8-AC76-49C9-AA13-7A67893D411DQ24240962-5172555E-25C3-4A95-A353-A7986FB0F52DQ24676809-5928FBE0-D8BB-4401-BE9F-0C1432C6CC32Q24801995-CB2F2F5B-0889-4005-B770-D6BA3D5B03AAQ24810256-D74417CE-7E54-45AE-BCC3-E48CDB839F61Q28080739-1B7B490E-A163-48A9-9CCC-06395F290928Q29619244-402BFEB0-7A93-41EE-8753-F7755E8DAB8CQ30351838-4A679DD1-2227-4927-B085-EF50E6F290E4Q30425111-855679F1-A6D1-4ACE-8AC3-6FE31E17FA78Q30425914-740E9E75-285B-42A2-8103-F671881EA0E0Q30436792-FB821E31-33EC-40A8-AF3E-F30BE599C9C0Q30541685-171B93F3-D1A9-4C00-AA73-7947D2C2FA69Q33298687-670A8FA3-1508-434F-88BA-70E349748A87Q33406769-EAA9CEBC-50CF-4E22-916B-76AF73513D88Q33638509-C2AC55A5-AE29-4B2C-A29D-CF8EA1958EB2Q33810625-3BDBBAB3-F797-4941-90DE-EDA0045BD3DAQ33991804-065FDA95-53DE-4E8C-89DE-DA398219F853Q34016364-40683584-31B0-48CD-BBED-80D157E3DA1FQ34034978-4B55C6BA-929D-4C6A-8E20-F59F1BCDC734Q34105959-70AEAFCC-D5CE-471D-83A6-DE05AC29BA09Q34267775-46B73075-BE5B-4119-9E06-38A7DE3A7C62Q34285656-25CB0BAC-DD63-404E-98EE-9F298A5A3743Q34379303-41FFCBB5-0066-4F18-9D36-4AA2F46C1959Q34380366-73843DA4-2324-43CF-A2EF-82E2F245A1BFQ34452719-D11667FB-CCD7-49ED-8564-307EDFA6F5E9Q34482064-E44412A5-6DBF-4D08-9C06-00B627381AD7Q34484042-1B0FEC19-0024-4F39-90B9-29B2AA4001A7Q34621713-EA76AF07-46A4-43E7-A58F-92CD8719A43AQ34972916-B88B89FE-AF20-4A11-89E8-BAE80009E54BQ34988018-A4E97CDE-0052-459D-BA27-9F5F90B96C76Q35034010-3F8F47A1-F68A-4F76-B3D5-AED81AD6E956Q35041705-87070539-4832-4AA3-A033-15EC1F30438AQ35058966-6A1C949D-289B-4636-A6FC-F59377937CF8Q35091692-17B7603C-4DF1-40DE-ADCC-0AC2F59E641AQ35125382-4B6AB214-20C1-4DF3-8F61-B37AC1F2CE61Q35614635-B5AEC1E0-C18D-4D7D-97A3-66CAA8674E62Q35681508-5DCB873A-BD0F-434D-A4C4-01D879646E79Q35791759-AAA5502B-6984-4799-B160-F3DC6EB9F9F4Q35842135-1C5D5414-2F03-4580-ABDD-CA2A22E0D3B4Q35899068-5FA63A49-B609-46B1-A569-FD0666FE5CD0
P2860
Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Immunization with a HER-2/neu ...... ll immunity in cancer patients
@ast
Immunization with a HER-2/neu ...... ll immunity in cancer patients
@en
type
label
Immunization with a HER-2/neu ...... ll immunity in cancer patients
@ast
Immunization with a HER-2/neu ...... ll immunity in cancer patients
@en
prefLabel
Immunization with a HER-2/neu ...... ll immunity in cancer patients
@ast
Immunization with a HER-2/neu ...... ll immunity in cancer patients
@en
P2093
P2860
P356
P1476
Immunization with a HER-2/neu ...... ll immunity in cancer patients
@en
P2093
K L Knutson
K Schiffman
P2860
P304
P356
10.1172/JCI11752
P407
P577
2001-02-01T00:00:00Z